Research programme: LRRK2 protein inhibitors - Ipsen/Oncodesign
Alternative Names: ODS 2005294; ODS200594Latest Information Update: 01 Mar 2023
Price :
$50 *
At a glance
- Originator Ipsen; Oncodesign Biotechnology
- Class Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 01 Mar 2023 Discontinued - Preclinical for Parkinson's disease in France (PO) (Oncodesign pipeline; February 2023)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in France (PO)
- 21 Oct 2015 Preclinical trials in Parkinson's disease in France (PO)